165 related articles for article (PubMed ID: 24134181)
1. Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment.
Venkatakrishnan K; Liu Y; Noe D; Mertz J; Bargfrede M; Marbury T; Farbakhsh K; Oliva C; Milton A
Br J Clin Pharmacol; 2014 Jun; 77(6):986-97. PubMed ID: 24134181
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment.
Venkatakrishnan K; Liu Y; Noe D; Mertz J; Bargfrede M; Marbury T; Farbakhsh K; Oliva C; Milton A
Br J Clin Pharmacol; 2014 Jun; 77(6):998-1010. PubMed ID: 24134216
[TBL] [Abstract][Full Text] [Related]
3. A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers.
Venkatakrishnan K; Kramer WG; Synold TW; Goodman DB; Sides E; Oliva C
Eur J Clin Pharmacol; 2012 Oct; 68(10):1347-55. PubMed ID: 22460239
[TBL] [Abstract][Full Text] [Related]
4. Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.
Anderson PM; Meyers P; Kleinerman E; Venkatakrishnan K; Hughes DP; Herzog C; Huh W; Sutphin R; Vyas YM; Shen V; Warwick A; Yeager N; Oliva C; Wang B; Liu Y; Chou A
Pediatr Blood Cancer; 2014 Feb; 61(2):238-44. PubMed ID: 23997016
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE.
Gay B; Cardot JM; Schnell C; van Hoogevest P; Gygax D
J Pharm Sci; 1993 Oct; 82(10):997-1001. PubMed ID: 8254500
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review.
Jimmy R; Stern C; Lisy K; White S
JBI Database System Rev Implement Rep; 2017 Aug; 15(8):2113-2152. PubMed ID: 28800058
[TBL] [Abstract][Full Text] [Related]
7. Mifamurtide: a review of its use in the treatment of osteosarcoma.
Frampton JE
Paediatr Drugs; 2010 Jun; 12(3):141-53. PubMed ID: 20481644
[TBL] [Abstract][Full Text] [Related]
8. Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine.
Drugs R D; 2008; 9(2):131-5. PubMed ID: 18298131
[TBL] [Abstract][Full Text] [Related]
9. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
Asano T; McWatters A; An T; Matsushima K; Kleinerman ES
J Pharmacol Exp Ther; 1994 Feb; 268(2):1032-9. PubMed ID: 8113959
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N
J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644
[TBL] [Abstract][Full Text] [Related]
11. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban.
Chang M; Yu Z; Shenker A; Wang J; Pursley J; Byon W; Boyd RA; LaCreta F; Frost CE
J Clin Pharmacol; 2016 May; 56(5):637-45. PubMed ID: 26358690
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.
Murray JL; Kleinerman ES; Cunningham JE; Tatom JR; Andrejcio K; Lepe-Zuniga J; Lamki LM; Rosenblum MG; Frost H; Gutterman JU
J Clin Oncol; 1989 Dec; 7(12):1915-25. PubMed ID: 2479721
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide.
Landmann R; Obrist R; Denz H; Ludwig C; Frost H; Wesp M; Rordorf C; Towbin H; Gygax D; Tarcsay L
Biotherapy; 1993; 7(1):1-12. PubMed ID: 8068481
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.
Martin DE; Chapelsky MC; Ilson B; Tenero D; Boike SC; Zariffa N; Jorkasky DK
J Clin Pharmacol; 1998 Feb; 38(2):129-37. PubMed ID: 9549643
[TBL] [Abstract][Full Text] [Related]
15. Liposomal MTP-PE.
Gano JB; Kleinerman ES
J Pediatr Oncol Nurs; 1994 Oct; 11(4):161-3. PubMed ID: 7946146
[No Abstract] [Full Text] [Related]
16. Orphan drugs revisited: cost-effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma.
Brosa M; García del Muro X; Mora J; Villacampa A; Pozo-Rubio T; Cubells L; Montoto C
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):331-40. PubMed ID: 25354299
[TBL] [Abstract][Full Text] [Related]
17. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir.
Cass LM; Efthymiopoulos C; Marsh J; Bye A
Clin Pharmacokinet; 1999; 36 Suppl 1():13-9. PubMed ID: 10429836
[TBL] [Abstract][Full Text] [Related]
18. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.
Maeda M; Knowles RD; Kleinerman ES
Cancer Commun; 1991; 3(10-11):313-21. PubMed ID: 1722107
[TBL] [Abstract][Full Text] [Related]
19. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of lipid-drug conjugates loaded into liposomes.
Signorell RD; Luciani P; Brambilla D; Leroux JC
Eur J Pharm Biopharm; 2018 Jul; 128():188-199. PubMed ID: 29678733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
